MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.

Gold Spot US Dollar, Silver Spot US Dollar, S&P 500, Dow Jones Industrial Average. Read 's Market Analysis on Investing.com ...

Some genetic mutations that are expected to completely stop a gene from working surprisingly cause only mild or even no symptoms. Researchers in previous studies have discovered one reason why: cells ...

Odds of a Fed rate cut in June nudge higher after 'core' consumer inflation comes in at its lowest rate in four years.

The enzyme Na⁺-NQR is a sodium pump that drives the respiration of many marine and pathogenic bacteria. Using redox reactions ...

XRP rebounded despite bearish technicals as investors focused on White House talks, ETF inflows, and progress toward the ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2025 and ...

From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...

The close connection between software stocks and high levels of intangible asset creation has hit our screens hard ...

Investing.com - Moderna (NASDAQ: MRNA) reported fourth quarter EPS of $-2.11, $0.51 better than the analyst estimate of $-2.62. Revenue for the quarter came in at $678M versus the consensus estimate ...